The 4 most recent market catalysts affecting $OCGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 85
What's Happening With Ocugen Stock Thursday?
Ocugen's interim analysis of its OCU410ST gene therapy trial revealed a negative treatment effect, a significant blow to a company heavily reliant on its pipeline. This clinical fa…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
Ocugen's Q2 earnings report presents a mixed bag for investors. The significant miss on EPS, falling short by 40% and showing a 40% decline year-over-year, is a negative signal reg…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
Ocugen received RMAT designation from the FDA for OCU410, a gene therapy for geographic atrophy. This is significant because RMAT designation is designed to accelerate the developm…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa
Ocugen has announced a licensing agreement with Roots Pharmaceutical for its gene therapy OCU400, targeting Retinitis Pigmentosa, specifically for the Middle East and North Africa …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.